LP
TVTX icon

LMR Partners’s Travere Therapeutics TVTX Stock Holding History

LMR Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.43M Buy
+182,900
New +$5.47M 0.01% 597

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LMR Partners's TVTX Position: Q1 2026 in Review

LMR Partners opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 1,220 shares worth $36.2K. The stake represents ﹤0.01% of the portfolio and ranks #1326 among its holdings. This is a return to the name: LMR Partners previously reported a position in TVTX as recently as Q4 2020.

LMR Partners first reported a position in TVTX in Q1 2015 and has held it in 3 quarters since. The position peaked at $899K in Q4 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • LMR Partners held 1,220 shares of Travere Therapeutics worth $36.2K as of Q1 2026.
  • Travere Therapeutics was a new LMR Partners position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1326 holding.
  • LMR Partners first reported a position in Travere Therapeutics in Q1 2015 and has held it in 3 quarters since.
  • LMR Partners's Travere Therapeutics position peaked at $899K in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.